Retirement Planning Co of New England Inc. Buys New Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Retirement Planning Co of New England Inc. purchased a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,370 shares of the company’s stock, valued at approximately $297,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Texas Permanent School Fund Corp lifted its position in shares of Pacira BioSciences by 1.4% during the first quarter. Texas Permanent School Fund Corp now owns 40,642 shares of the company’s stock valued at $1,188,000 after purchasing an additional 543 shares in the last quarter. Duality Advisers LP increased its stake in Pacira BioSciences by 1.8% in the 1st quarter. Duality Advisers LP now owns 34,784 shares of the company’s stock valued at $1,016,000 after buying an additional 605 shares during the last quarter. Inspire Investing LLC lifted its position in shares of Pacira BioSciences by 5.9% during the 1st quarter. Inspire Investing LLC now owns 12,131 shares of the company’s stock worth $354,000 after buying an additional 675 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Pacira BioSciences by 61.5% in the 4th quarter. Quadrant Capital Group LLC now owns 2,324 shares of the company’s stock worth $78,000 after buying an additional 885 shares during the last quarter. Finally, ICA Group Wealth Management LLC bought a new position in shares of Pacira BioSciences in the fourth quarter valued at approximately $30,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PCRX has been the topic of several research analyst reports. HC Wainwright cut their price objective on Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Royal Bank of Canada cut Pacira BioSciences from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $37.00 to $14.00 in a research note on Monday, August 12th. JPMorgan Chase & Co. restated an “underweight” rating and set a $10.00 price target (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. Truist Financial lowered shares of Pacira BioSciences from a “buy” rating to a “sell” rating and lowered their price objective for the stock from $30.00 to $8.00 in a research report on Tuesday, August 13th. Finally, Raymond James cut shares of Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research note on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Pacira BioSciences presently has an average rating of “Hold” and a consensus price target of $24.78.

Pacira BioSciences Stock Performance

Shares of PCRX stock opened at $13.11 on Friday. The firm’s 50 day moving average is $17.16 and its 200 day moving average is $24.52. The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.67. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95. The stock has a market capitalization of $604.76 million, a P/E ratio of 9.17 and a beta of 0.84.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.53 by $0.11. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The firm had revenue of $178.02 million for the quarter, compared to the consensus estimate of $173.31 million. On average, sell-side analysts anticipate that Pacira BioSciences, Inc. will post 2.24 earnings per share for the current year.

Insider Buying and Selling

In other Pacira BioSciences news, insider Jonathan Slonin sold 2,836 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total value of $80,117.00. Following the sale, the insider now owns 95,557 shares of the company’s stock, valued at approximately $2,699,485.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Jonathan Slonin sold 2,836 shares of the stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $28.25, for a total value of $80,117.00. Following the transaction, the insider now owns 95,557 shares of the company’s stock, valued at approximately $2,699,485.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Frank D. Lee acquired 8,264 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were bought at an average cost of $12.10 per share, with a total value of $99,994.40. Following the completion of the acquisition, the chief executive officer now directly owns 107,784 shares in the company, valued at approximately $1,304,186.40. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 11,176 shares of company stock worth $136,240 and sold 4,281 shares worth $105,494. 6.40% of the stock is owned by company insiders.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.